1. Home
  2. COE vs TLSA Comparison

COE vs TLSA Comparison

Compare COE & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

COE

51Talk Online Education Group

HOLD

Current Price

$16.05

Market Cap

140.9M

Sector

Real Estate

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.29

Market Cap

155.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COE
TLSA
Founded
2011
2013
Country
Singapore
United Kingdom
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
140.9M
155.3M
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
COE
TLSA
Price
$16.05
$1.29
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.4K
203.3K
Earning Date
06-08-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.66
$1.04
52 Week High
$56.13
$2.60

Technical Indicators

Market Signals
Indicator
COE
TLSA
Relative Strength Index (RSI) 30.44 55.55
Support Level $15.32 $1.26
Resistance Level $28.26 $1.44
Average True Range (ATR) 1.73 0.08
MACD -0.19 0.02
Stochastic Oscillator 18.05 96.15

Price Performance

Historical Comparison
COE
TLSA

About COE 51Talk Online Education Group

51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in seven principal geographical area: China, Hong Kong, Philippines, Singapore, Malaysia, Thailand and Saudi Arabia.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: